Upon administration, CD24-Fc immediately binds to injured tumor cell components and prevents the interaction of DAMPs with toll-like receptors (TLRs) inhibiting both nuclear factor-kappa B (NFkB) activation and secretion of inflammatory cytokines, which may dampen tumor immunity induced by the vaccine (24). This evidence concerns the gene NFKB1 and neoplasm.